Loading NexProTools...

Preparing interactive calculation engine

Tools Medical & ClinicalApoB & Cardiovascular Risk Matrix

Atherogenic Particle Count & Discordance Engine

ApoB & Cardiovascular Longevity Risk Matrix

Evaluate exact atherogenic lipoprotein particle counts, identify hidden ApoB vs LDL-C discordance, and determine clinical lipid targets based on European Society of Cardiology (ESC) & National Lipid Association (NLA) consensus guidelines.

Patient Biomarkers & Lipid Panel Inputs

ESC 2026 Guidelines

Apolipoprotein B (ApoB)95 mg/dL

Total count of atherogenic particles.

LDL Cholesterol (LDL-C)120 mg/dL

Cholesterol mass inside LDL particles.

Triglycerides160 mg/dL

Rich in VLDL / Remnant particles.

HDL Cholesterol (HDL-C)50 mg/dL

Cardioprotective reverse transport.

Atherogenic Particle Concentration

95mg/dL

50th to 65th Percentile

Borderline Elevated (80–100 mg/dL)

Non-HDL Cholesterol

152 mg/dL

Target: < 100 mg/dL

TG / HDL Ratio

3.2

⚠️ Insulin Resistance Proxy

ApoB / LDL-C Ratio

0.79

Buoyant Particles

Clinical Guideline-Directed Lipid Targets (ESC / NLA / AHA)

•Primary Prevention Target: Maintain ApoB < 80 mg/dL through saturated fat reduction, dietary fiber escalation, and moderate-intensity statin therapy if indicated.

•High-Risk / Coronary Calcium (CAC > 0): Target ApoB < 65 mg/dL (or LDL-C < 70 mg/dL). Add Ezetimibe 10mg if statin monotherapy fails to achieve goal.

•Secondary Prevention (Post-MI / Stent): Target ApoB < 50 mg/dL (or LDL-C < 55 mg/dL) using high-intensity statin + Ezetimibe + PCSK9 inhibitors (Evolocumab / Alirocumab).

Why ApoB Trumps LDL-C

Every single atherogenic lipoprotein (LDL, VLDL, IDL, Lp(a)) contains exactly one single molecule of Apolipoprotein B-100.

While LDL-C measures the total weight of cholesterol inside particles, ApoB measures the exact physical number of particles capable of penetrating the arterial endothelial wall and initiating atherosclerosis.

Read the ApoB Lipidology Masterclass

Learn the Mendelian randomization clinical evidence proving that cumulative lifetime ApoB exposure is the causal driver of coronary artery disease.

Read Masterclass Guide

Clinical Lipidology Notice:Synthesized from the 2019/2026 ESC/EAS Guidelines for the Management of Dyslipidaemias and National Lipid Association (NLA) Scientific Statements. Risk assessments represent statistical models; consult a board-certified cardiologist or lipidologist for personalized pharmacotherapy.